Study of CoronaVac reaches minimum of infected and enters the final stage


posted on 23/11/2020 15:20 / updated 23/11/2020 15:22

(credit: SILVIO AVILA / AFP)

The government of the state of São Paulo announced on Monday (23/11) that the clinical study of the CoronaVac vaccine, produced by the Chinese company Sinovac in partnership with the Butantan Institute, has reached its final stage. Results are expected in the first week of December.

According to the director of the Butantan Institute, Dimas Covas, the study reached the minimum number of 61 infected with the new coronavirus, necessary to evaluate the effectiveness of the immunizer. In all, 74 cases of covid-19 were identified among the volunteers who received the vaccine dose or the placebo.

“The analysis of the cases has already started and, therefore, quickly in the first week of December, we will have the result of these analyzes”, indicated Covas.

After that, the results will be sent to the Independent International Committee to validate the result and produce the report that will be sent to the National Health Surveillance Agency (Anvisa).


Dimas Covas reported that more than 10,000 volunteers were vaccinated. Half received a placebo and half received the vaccine. “In this group of people 74 cases of covid-19 appeared and, now, what the teams do is to identify the cases to see if they appeared in those who received the placebo or the vaccine. If all the cases appeared in those who received the placebo , this would mean that the effectiveness is 100% “, he indicated.

The Secretary of State for Health of São Paulo, Jean Gorinchteyn, celebrated the speed of the study. “Only with the vaccine, we will live our normal. Until then, we need to remember that we are in quarantine and all behavior must be responsible, maintaining all health rules, social distance and wearing masks”, he said.

Source link by

*The article has been translated based on the content of Source link by
. If there is any problem regarding the content, copyright, please leave a report below the article. We will try to process as quickly as possible to protect the rights of the author. Thank you very much!

*We just want readers to access information more quickly and easily with other multilingual content, instead of information only available in a certain language.

*We always respect the copyright of the content of the author and always include the original link of the source article.If the author disagrees, just leave the report below the article, the article will be edited or deleted at the request of the author. Thanks very much! Best regards!


Please enter your comment!
Please enter your name here